NOCIL Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- NOCIL Ltd reported a 16.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 3.7%.
- Its expenses for the quarter were up by 5.7% QoQ and down 8.8% YoY.
- The net profit increased 222.0% QoQ and increased 46.7% YoY.
- The earnings per share (EPS) of NOCIL Ltd stood at 2.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 381.21 | 327.21 | 395.66 | 16.5% | -3.7% |
Total Expenses | 325.61 | 308.12 | 357.13 | 5.7% | -8.8% |
Profit Before Tax | 55.60 | 19.09 | 38.53 | 191.3% | 44.3% |
Tax | 14.06 | 6.19 | 10.21 | 127.1% | 37.7% |
Profit After Tax | 41.54 | 12.90 | 28.32 | 222.0% | 46.7% |
Earnings Per Share | 2.50 | 0.80 | 1.70 | 212.5% | 47.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
NOCIL Ltd is a leading manufacturer of rubber chemicals, operating primarily within the chemical manufacturing industry. The company is known for its robust portfolio of various rubber chemicals utilized in the production of automotive tires and industrial goods. NOCIL Ltd holds a significant position in the market due to its established manufacturing capabilities and extensive distribution network. As of the latest updates available until October 2023, NOCIL has focused on expanding its production capacity and enhancing its product offerings to meet the growing demand in both domestic and international markets. However, further specific recent developments regarding the company are not available in the given data.
Revenue
During the fourth quarter of the fiscal year 2025 (Q4FY25), NOCIL Ltd reported a total income of ₹381.21 crores. This marks a 16.5% increase from the previous quarter (Q3FY25), where the total income was ₹327.21 crores. When compared to the same quarter in the previous fiscal year (Q4FY24), where the total income stood at ₹395.66 crores, there is a 3.7% year-over-year decline. This quarterly increase reflects a positive momentum in revenue generation, while the year-over-year comparison shows a slight contraction. The data indicates fluctuations in the company's revenue over time, which could be attributed to various dynamic factors in the industry and market conditions.
Profitability
NOCIL Ltd's profitability showed significant improvement in Q4FY25. The profit before tax was recorded at ₹55.60 crores, a substantial increase from ₹19.09 crores in Q3FY25, representing a 191.3% quarter-over-quarter growth. Compared to the same quarter the previous year, where the profit before tax was ₹38.53 crores, there is a 44.3% year-over-year increase. After accounting for taxes, the profit after tax in Q4FY25 was ₹41.54 crores, which is a remarkable 222.0% increase from ₹12.90 crores in Q3FY25 and a 46.7% increase from ₹28.32 crores in Q4FY24. This robust growth in profitability indicates a strong financial performance during the quarter. The earnings per share (EPS) also saw a significant rise to ₹2.50 in Q4FY25 from ₹0.80 in Q3FY25 and ₹1.70 in Q4FY24, reflecting a 212.5% QoQ and 47.1% YoY increase.
Operating Metrics
The total expenses for NOCIL Ltd in Q4FY25 were ₹325.61 crores, which is a 5.7% increase from the previous quarter (₹308.12 crores in Q3FY25). When compared to Q4FY24, where total expenses were ₹357.13 crores, there is an 8.8% decrease year-over-year. The tax expense for Q4FY25 stood at ₹14.06 crores, reflecting a 127.1% increase compared to the previous quarter and a 37.7% increase year-over-year. These figures illustrate a notable increase in tax obligations, aligned with the rise in profitability. The financial data reveals a tightening of expenses relative to income, suggesting efficient cost management strategies. The trends in these operating metrics provide insights into the company's operational efficiency and financial health.